IL-9 and TSLP could be other targets to inhibit Th2 responses in COVID-19 patients, as these molecules promote allergic inflammation (Temann and others 2002; Ito and others 2012; Koch and others 2017). This evidence concerns the gene IL9 and COVID-19.